{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:19:21Z","timestamp":1789024761814,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015060","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000}}],"reference-count":133,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015060.pub2","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T06:24:12Z","timestamp":1718173452000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunosuppressive therapy for IgA nephropathy in children"],"prefix":"10.1002","volume":"2024","author":[{"given":"Areefa","family":"Alladin","sequence":"additional","affiliation":[{"name":"Departments of Paediatrics and Community Health Sciences; University of Calgary; Calgary Canada"},{"name":"School of Medicine; University of Guyana; Georgetown Guyana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Nephrology; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M","family":"Hodson","sequence":"additional","affiliation":[{"name":"Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ravani","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences; Cumming School of Medicine, University of Calgary; Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Pfister","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Calgary; Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"Quinn","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences; Cumming School of Medicine, University of Calgary; Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Samuel","sequence":"additional","affiliation":[{"name":"Departments of Paediatrics and Community Health Sciences; University of Calgary; Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"Abstracts","key":"10.1002\/14651858.CD015060.pub2-BIB0001|cit1","first-page":"48A","article-title":"Reduction of proteinuria observed in response to high dose ACE inhibition and omega-3 fatty acids in pts with IgA nephropathy. Report from the second North American IgA nephropathy trial [abstract no: SA-FC059]","volume":"18","author":"Hogg","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2215\/CJN.01020905","article-title":"Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD015060.pub2-BIB0004|cit4","first-page":"523","article-title":"Dose-dependency of the effect of omega-3 fatty acids (O3FA) on proteinuria in patients with IgA nephropathy: report from the 2nd North American IgA nephropathy trial [abstract no: F-PO860]","volume":"16","author":"Hogg","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Nov","key":"10.1002\/14651858.CD015060.pub2-BIB0006|cit6","first-page":"751A","article-title":"Multicenter, placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group [abstract no: SU-PO979]","volume":"14","author":"Hogg","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"467\u201374","DOI":"10.2215\/CJN.01020905","article-title":"Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA Nephropathy: Report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0008|cit8","first-page":"C64","article-title":"Clinical trial of alternate-day prednisone or daily omega-3 fatty acids in patients with IgA nephropathy [abstract no: OFC10]","volume":"19","author":"Hogg","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0009|cit9","first-page":"511-6","article-title":"Advances in treatment: immunoglobulin A nephropathy","volume":"16","author":"Hogg","year":"1996","journal-title":"Seminars in nephrology"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0272-6386(95)90445-X","article-title":"A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study","volume":"26","author":"Hogg","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/IJNRD.S24684","article-title":"Outcome results in children with IgA nephropathy: A single center experience","volume":"5","author":"Bulut","year":"2012","journal-title":"International Journal of Nephrology & Renovascular Disease"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0012|cit12","first-page":"916\u201325","article-title":"Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features","volume":"3","author":"Cambier","year":"2018","journal-title":"KI Reports"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00467-003-1205-2","article-title":"Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study","volume":"18","author":"Chan","year":"2003","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1014424723466","article-title":"Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria","volume":"33","author":"Harmankaya","year":"2002","journal-title":"International Urology & Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-5-3","article-title":"A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]","volume":"5","author":"Hogg","year":"2004","journal-title":"BMC Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Hogg RJ SouthWest PNSG A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy: study protocol Personal communication 2003","DOI":"10.1186\/1471-2369-5-3"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10157-017-1515-5","article-title":"Comparison of long-term follow-up outcomes between multiple-drugs combination therapy and tonsillectomy pulse therapy for pediatric IgA nephropathy","volume":"22","author":"Kawasaki","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD015060.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00467-006-0272-6","article-title":"Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy","volume":"21","author":"Kawasaki","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0020|cit20","first-page":"C4","article-title":"Randomized, prospective, multcenter trial for treatment of IgA nephropathy in children [abstract no: S-5]","volume":"10","author":"Koitabashi","year":"1996","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0021|cit21","first-page":"1880","article-title":"Early corticosteroid treatment (CT) in children with IgA nephropathy (IGAN): A randomized and controlled trial [abstract no: 429]","volume":"25","author":"Nuzzi","year":"2010","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0022|cit22","first-page":"1781","article-title":"Early corticosteroid treatment in children with IGA nephropathy: a randomized and controlled trial [abstract no: OC005]","volume":"24","author":"Nuzzi","year":"2009","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0023|cit23","unstructured":"Nuzzi F D'Armiento M Malgieri G Ferretti A Marzano L Pecoraro C Early corticosteroid treatment in children with IGA nephropathy: a randomized and controlled trial Transplantation Society of Australia & New Zealand (TSANZ). 27th annual meeting; 2009 Jun 17-19; Canberra (ACT) 2009 28"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3476(05)81808-6","article-title":"Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis","volume":"121","author":"Welch","year":"1992","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"270\u20134","DOI":"10.1007\/s10157-003-0255-x","article-title":"Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy","volume":"7","author":"Yagi","year":"2003","journal-title":"Clinical & Experimental Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0026|cit26","first-page":"C208","article-title":"Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]","volume":"6","author":"Ito","year":"1992","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD015060.pub2-BIB0030|cit30","first-page":"C31","article-title":"Corticosteroids and immunosuppressive drugs [abstract no: S8.2]","volume":"16","author":"Yoshikawa","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0031|cit31","first-page":"1401","article-title":"A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract no: A0779]","volume":"7","author":"Yoshikawa","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"Yoshikawa","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Sept","key":"10.1002\/14651858.CD015060.pub2-BIB0033|cit33","first-page":"79A","article-title":"Prednisolone therapy versus combined therapy with prednisolone, azathioprine, warfarin and dipyridamole for newly diagnosed severe childhood IgA nephropathy: a controlled trial by the Japanese Pediatric IgA Nephropathy Treatment study group [abstract no: A0430]","volume":"11","author":"Yoshikawa","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0034|cit34","first-page":"C57","article-title":"Treatment of IGA nephropathy in children [abstract no: FCP04]","volume":"19","author":"Yoshikawa","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0035|cit35","first-page":"302\u20134","article-title":"Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy","volume":"17","author":"Bhattacharjee","year":"2002","journal-title":"Pediatric Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0036|cit36","first-page":"136","article-title":"One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study","volume":"18","author":"Dal Canton","year":"2005","journal-title":"Journal of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD015060.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2121\u20137","DOI":"10.1007\/s00467-015-3176-5","article-title":"Long-term outcome of childhood IgA nephropathy with minimal proteinuria","volume":"30","author":"Higa","year":"2015","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA Nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0039|cit39","unstructured":"Effect of tonsillectomy on longterm renal outcome of ig a nephropathy clinicaltrials.gov\/ct2\/show\/NCT02471599 2015"},{"issue":"11","key":"10.1002\/14651858.CD015060.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","article-title":"Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT","volume":"33","author":"Shima","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1600141","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Ayoub","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.kint.2020.05.033","article-title":"Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial","volume":"98","author":"Cheung","year":"2020","journal-title":"Kidney international"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0043|cit43","first-page":"284","article-title":"Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol","volume":"21","author":"Eitner","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015060.pub2-BIB0044|cit44","first-page":"B4","article-title":"Corticosteroid monotherapy versus combined immunosuppression in IgA nephropathy: insights from the STOP-IgAN trial [abstract no: SA-PO1097]","volume":"26","author":"Floege","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0045|cit45","unstructured":"Floege J Rauen T Eitner F Fitzner C Sommerer C Zeier M Supportive versus immunosuppressive therapy for progressive IgA nephropathy (STOP-IGAN): a randomized, controlled, open-label multicenter trial [abstract] 52nd Congress ERA-EDTA; 2015 May 28-31; London, UK 2015"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015060.pub2-BIB0046|cit46","article-title":"Galactose-deficient Iga1 levels predict renal outcome in the STOP-IgAN trial cohort [abstract no: 3409]","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0047|cit47","first-page":"992","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Floege","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015060.pub2-BIB0048|cit48","first-page":"14A","article-title":"The MEST kidney biopsy score predicts renal outcome in STOP-IgAN trial patients - a post-hoc study [abstract no: TH-OR057]","volume":"27","author":"Floege","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0049|cit49","unstructured":"Floege J Wied S Fitzner C Eitner F Sommerer C Zeier M Intensive supportive care plus immunosuppression in IgA nephropathy: long-term renal outcomes [abstract no: TH-PO1208] www.asn-online.org\/education\/kidneyweek\/2019\/program-abstract.aspx?controlId=3261159 2019"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD015060.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.ekir.2019.05.416","article-title":"SUN-021 Dual blockade of the renin-angiotensin system in patients with IgA nephropathy - insights from the STOP-IGAN Trial [abstract]","volume":"4","author":"Lennartz","year":"2019","journal-title":"Kidney International Reports"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015060.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.ekir.2020.02.419","article-title":"SAT-395 Dual blockade of the renin-angiotensin system in patients with IgA nephropathy [abstract]","volume":"5","author":"Lennartz","year":"2020","journal-title":"Kidney International Reports"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40620-020-00836-8","article-title":"Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy","volume":"33","author":"Lennartz","year":"2020","journal-title":"Journal of Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD015060.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0055|cit55","first-page":"141","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy-insights from the Stop-IgAN Trial [abstract]","volume":"4","author":"Rauen","year":"2018","journal-title":"Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1600141","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Robert","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0058|cit58","first-page":"992","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"374","author":"Schena","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12882-018-1128-6","article-title":"Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)","volume":"19","author":"Schimpf","year":"2018","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0060|cit60","unstructured":"Mycophenolate mofetil versus intravenous cyclophosphamide pulses in the treatment of crescentic IgA nephropathy clinicaltrials.gov\/show\/NCT00301600"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0061|cit61","unstructured":"Mycophenolate mofetil (MMF) in patients with IgA nephropathy (IgAN) clinicaltrials.gov\/show\/NCT00657059"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/children9050653","article-title":"Management of IgA nephropathy in pediatric patients","volume":"9","author":"Schroda","year":"2022","journal-title":"Children"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0063|cit63","unstructured":"Ding J Mizoribine for the treatment of pediatric IgA nephropathy trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-TRC-13003038"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0064|cit64","unstructured":"Leflunomide plus low dose corticosteroid in immunoglobulin A (IgA) nephropathy with renal insufficiency clinicaltrials.gov\/show\/NCT04020328"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0065|cit65","unstructured":"Steroids therapy in IgA nephropathy with crescents clinicaltrials.gov\/show\/NCT04833374"},{"issue":"11","key":"10.1002\/14651858.CD015060.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1007\/s00467-023-05968-0","article-title":"A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide","volume":"38","author":"Antonucci","year":"2023","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.kint.2020.10.033","article-title":"Updating the International IgA Nephropathy Prediction Tool for use in children","volume":"99","author":"Barbour","year":"2021","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.kint.2018.12.018","article-title":"Health-related quality of life in glomerular disease","volume":"95","author":"Canetta","year":"2019","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"669\u201373","DOI":"10.1016\/j.kint.2022.05.034","article-title":"First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy","volume":"103","author":"Cheung","year":"2023","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The gut-renal connection in IgA nephropathy","volume":"38","author":"Coppo","year":"2018","journal-title":"Seminars in Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40620-020-00725-0","article-title":"IgA nephropathy in children and in adults: two separate entities or the same disease?","volume":"33","author":"Coppo","year":"2020","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"491\u20136","DOI":"10.1007\/s00467-020-04486-7","article-title":"Treatment of IgA nephropathy in children: a land without KDIGO guidance","volume":"36","author":"Coppo","year":"2021","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0075|cit75","first-page":"1373","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA Nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"KI Reports"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD015060.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jval.2022.09.2211","article-title":"PCR278 Systematic review on health-related quality of life and utilities in immunoglobulin A Nephropathy (IgAN) [abstract]","volume":"25","author":"Doherty","year":"2022","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11255-016-1432-7","article-title":"Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis","volume":"49","author":"Duan","year":"2017","journal-title":"International Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/j.ajkd.2011.03.024","article-title":"IgA nephropathy: progress before and since Berger","volume":"58","author":"Feehally","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"7","key":"10.1002\/14651858.CD015060.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneph.2016.84","article-title":"Glomerular disease: immunosuppressant-induced reduction of proteinuria in IgAN","volume":"12","author":"Floege","year":"2016","journal-title":"Nature Reviews Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD015060.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2464\u201373","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults-treatment standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7650","key":"10.1002\/14651858.CD015060.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD015060.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1681\/ASN.2012010063","article-title":"Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria","volume":"23","author":"Gutierrez","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"26","key":"10.1002\/14651858.CD015060.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"352","author":"Halloran","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD015060.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0088|cit88","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"715253","DOI":"10.3389\/fphar.2021.715253","article-title":"An update on targeted treatment of IgA nephropathy: an autoimmune perspective","volume":"12","author":"Huang","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00467-014-3019-9","article-title":"Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy","volume":"30","author":"Kamei","year":"2015","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e9231989","DOI":"10.1155\/2018\/9231989","article-title":"Atypical presentation of IgA nephropathy mimicking acute pyelonephritis","volume":"2018","author":"Karakonstantis","year":"2018","journal-title":"Case Reports in Medicine"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"681482","DOI":"10.1155\/2009\/681482","article-title":"Mizoribine: a new approach in the treatment of renal disease","volume":"2009","author":"Kawasaki","year":"2009","journal-title":"Clinical & Developmental Immunology"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10157-017-1515-5","article-title":"Comparison of long-term follow-up outcomes between multiple-drugs combination therapy and tonsillectomy pulse therapy for pediatric IgA nephropathy","volume":"22","author":"Kawasaki","year":"2018","journal-title":"Clinical & Experimental Nephrology"},{"issue":"4S","key":"10.1002\/14651858.CD015060.pub2-BIB0096|cit96","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00467-019-04415-3","article-title":"Prediction of renal outcome in Henoch-Schonlein nephritis based on biopsy findings","volume":"35","author":"Koskela","year":"2020","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/aoms.2020.100367","article-title":"Health-related quality of life in children with immunoglobulin A nephropathy \u2013 results of a multicentre national study","volume":"17","author":"Mizerska-Wasiak","year":"2021","journal-title":"Archives of Medical Science"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","article-title":"Immunoglobulin A nephropathy. Recurrence after renal transplantation","volume":"10","author":"Moroni","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015060.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965.pub3","article-title":"Immunosuppressive agents for treating IgA nephropathy","author":"Natale","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"391\u2013402","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0105|cit105","volume-title":"StatPearls","author":"Ogino","year":"2021"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD015060.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9156","key":"10.1002\/14651858.CD015060.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"issue":"10417","key":"10.1002\/14651858.CD015060.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2077\u201390","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT)): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.34067\/KID.0002382022","article-title":"The gut and kidney crosstalk in immunoglobulin A nephropathy","volume":"3","author":"Sanchez-Russo","year":"2022","journal-title":"Kidney360"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Seminars in Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0116|cit116","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0117|cit117","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000519973","article-title":"New Insights into the Pathogenesis and Treatment Strategies in IgA Nephropathy","volume":"2","author":"Scionti","year":"2022","journal-title":"Glomerular Dis"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10157-019-01700-1","article-title":"New strategies and perspectives on managing IgA nephropathy","volume":"23","author":"Selvaskandan","year":"2019","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0120|cit120","unstructured":"The SONG Handbook Version 1.0 www.songinitiative.org\/ 2017"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-2125.2005.02445.x","article-title":"How children's responses to drugs differ from adults","volume":"59","author":"Stephenson","year":"2005","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"23","key":"10.1002\/14651858.CD015060.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD015060.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1888\u201398","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD015060.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD015060.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respiratory Care"},{"issue":"25","key":"10.1002\/14651858.CD015060.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015060.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD015060.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD015060.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s11255-019-02255-6","article-title":"Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis","volume":"51","author":"Yi","year":"2019","journal-title":"International Urology & Nephrology"},{"key":"10.1002\/14651858.CD015060.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"921253","DOI":"10.1155\/2013\/921253","article-title":"Assessment of behavior abnormalities of corticosteroids in children with nephrotic syndrome","volume":"2013","author":"Youssef","year":"2013","journal-title":"ISRN Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD015060.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10157-015-1223-y","article-title":"Evidence-based clinical practice guidelines for IgA nephropathy 2014","volume":"20","author":"Yuzawa","year":"2016","journal-title":"Clinical & Experimental Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD015060.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/ndt\/gfu068","article-title":"Does tonsillectomy have a role in the treatment of patients with immunoglobulin A nephropathy?","volume":"29","author":"Zand","year":"2014","journal-title":"Nephrology Dialysis Transplantation"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:32:37Z","timestamp":1761823957000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015060.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":133,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015060.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}